The abstract is read at the publisher; the summary is JClub's.
FLT3-ITD microclones (allelic ratio 0.0004–0.05) in newly diagnosed AML patients are linked to higher relapse risk, with 2-year relapse reaching 45.1%.
- Why it matters: Current risk models rely on FLT3-ITD macroclones, leaving the prognostic significance of low-level microclones uncertain for patients treated with intensive chemotherapy.
- What they did: In a post hoc NGS analysis of 1733 newly diagnosed AML patients from the Backbone Intergroup 1 trial, microclones were detected in 17.4% of patients without macroclones and analyzed with adjusted cause-specific hazard ratios.
- The result: Microclones and macroclones were independently associated with increased relapse risk (HR 1.50 and 1.98), and 41.8% of relapses arising from microclones at diagnosis involved a macroclone at relapse.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.